Aytu BioScience

Executive Summary

Aytu BioScience is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare pediatric conditions and other high-need medical areas. The company's portfolio includes FDA-approved products for attention deficit hyperactivity disorder (ADHD) and rare pediatric sleep disorders, providing a recurring revenue base. Aytu's lead commercial product, ADZENYS XR-ODT, is an amphetamine extended-release orally disintegrating tablet for ADHD. The company also markets Tuzistra XR for cough and other prescription products. Despite a modest market capitalization of approximately $29 million, Aytu has established a commercial footprint and a pipeline targeting ultra-rare diseases with significant unmet need. Aytu's pipeline is anchored by enzastaurin, a Phase 3 candidate for Vascular Ehlers-Danlos Syndrome (vEDS), a life-threatening genetic disorder with no approved therapies. The ongoing Phase 3 trial (NCT05463679) is active and expected to complete in early 2027, with data readout anticipated in the second half of 2026. Positive results could address a critical unmet need and unlock substantial value. The company's strategy balances near-term revenue from approved products with high-risk, high-reward pipeline opportunities. Key risks include clinical trial outcomes, competitive dynamics, and the need for additional capital. Overall, Aytu represents a speculative investment with potential upside from pipeline milestones.

Upcoming Catalysts (preview)

• H2 2026Enzastaurin Phase 3 Data Readout for vEDS40% success
• TBDPotential FDA Approval or Label Expansion for ADZENYS XR-ODT30% success
• Q2 2026Quarterly Earnings and Revenue Growth from Commercial Portfolio60% success